Fosamax (alendronate) to PREVENT osteoporosis in postmenopausal women

    Merck is now promoting Fosamax (alendronate) to PREVENT osteoporosis in postmenopausal women.

    It was initially approved just for treatment.

    Fosamax slows bone loss and increases bone density. It seems to work as well as estrogen to prevent osteoporosis.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote